Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 302

1.

Multiple Routes to Oncogenesis are Promoted by the Human Papillomavirus-Host Protein Network.

Eckhardt M, Zhang W, Gross AM, Von Dollen J, Johnson JR, Franks-Skiba KE, Swaney DL, Johnson TL, Jang GM, Shah PS, Brand TM, Archambault J, Kreisberg JF, Grandis JR, Ideker T, Krogan NJ.

Cancer Discov. 2018 Sep 12. pii: CD-17-1018. doi: 10.1158/2159-8290.CD-17-1018. [Epub ahead of print]

PMID:
30209081
2.

STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer.

Njatcha C, Farooqui M, Kornberg A, Johnson DE, Grandis JR, Siegfried JM.

Mol Cancer Ther. 2018 Sep;17(9):1917-1926. doi: 10.1158/1535-7163.MCT-17-1194. Epub 2018 Jun 11.

PMID:
29891486
3.

Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor.

Lee DS, O'Keefe RA, Ha PK, Grandis JR, Johnson DE.

Int J Mol Sci. 2018 May 30;19(6). pii: E1608. doi: 10.3390/ijms19061608.

4.

BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.

Leonard B, Brand TM, O'Keefe RA, Lee ED, Zeng Y, Kemmer JD, Li H, Grandis JR, Bhola NE.

Cancer Res. 2018 Aug 1;78(15):4331-4343. doi: 10.1158/0008-5472.CAN-18-0459. Epub 2018 May 23.

PMID:
29792310
5.

New Therapies in Head and Neck Cancer.

Santuray RT, Johnson DE, Grandis JR.

Trends Cancer. 2018 May;4(5):385-396. doi: 10.1016/j.trecan.2018.03.006. Epub 2018 Apr 19. Review.

PMID:
29709262
6.

Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.

Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR.

Cancer Res. 2018 May 1;78(9):2383-2395. doi: 10.1158/0008-5472.CAN-17-1672. Epub 2018 Feb 12.

PMID:
29440171
7.

Leveraging Genomics for Head and Neck Cancer Treatment.

Kemmer JD, Johnson DE, Grandis JR.

J Dent Res. 2018 Jun;97(6):603-613. doi: 10.1177/0022034518756352. Epub 2018 Feb 8.

PMID:
29420101
8.

Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Johnson DE, O'Keefe RA, Grandis JR.

Nat Rev Clin Oncol. 2018 Apr;15(4):234-248. doi: 10.1038/nrclinonc.2018.8. Epub 2018 Feb 6. Review.

PMID:
29405201
9.

Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer.

Cho J, Johnson DE, Grandis JR.

Semin Radiat Oncol. 2018 Jan;28(1):2-11. doi: 10.1016/j.semradonc.2017.08.005. Review.

PMID:
29173752
10.

The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma.

Zhong Q, Liu ZH, Lin ZR, Hu ZD, Yuan L, Liu YM, Zhou AJ, Xu LH, Hu LJ, Wang ZF, Guan XY, Hao JJ, Lui VWY, Guo L, Mai HQ, Chen MY, Han F, Xia YF, Grandis JR, Zhang X, Zeng MS.

Clin Cancer Res. 2018 Feb 1;24(3):659-673. doi: 10.1158/1078-0432.CCR-17-0352. Epub 2017 Nov 13.

PMID:
29133573
11.

High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines.

Johnston PA, Sen M, Hua Y, Camarco DP, Shun TY, Lazo JS, Grandis JR.

Methods Mol Biol. 2018;1683:229-244. doi: 10.1007/978-1-4939-7357-6_14. Erratum in: Methods Mol Biol. 2018;1683:E1.

PMID:
29082496
12.

Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma.

Zhang H, Kim S, Chen Z, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, Wolf GT, Walline HM, Bellile E, Riddell J 4th, Pai SI, Sidransky D, Westra WH, William WN Jr, Lee JJ, El-Naggar AK, Ferris RL, Seethala R, Grandis JR, Chen ZG, Saba NF, Shin DM; Head and Neck Cancer SPORE HIV supplement consortium.

Head Neck. 2017 Dec;39(12):2433-2443. doi: 10.1002/hed.24911. Epub 2017 Sep 25.

PMID:
28945296
13.

EGFR-targeted therapies in the post-genomic era.

Xu MJ, Johnson DE, Grandis JR.

Cancer Metastasis Rev. 2017 Sep;36(3):463-473. doi: 10.1007/s10555-017-9687-8. Review.

14.

Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines.

Sen M, Johnston PA, Pollock NI, DeGrave K, Joyce SC, Freilino ML, Hua Y, Camarco DP, Close DA, Huryn DM, Wipf P, Grandis JR.

J Chem Biol. 2017 May 11;10(3):129-141. doi: 10.1007/s12154-017-0169-9. eCollection 2017 Jul.

15.

The fourth edition of the head and neck World Health Organization blue book: editors' perspectives.

El-Naggar AK, Chan JKC, Takata T, Grandis JR, Slootweg PJ.

Hum Pathol. 2017 Aug;66:10-12. doi: 10.1016/j.humpath.2017.05.014. Epub 2017 Jun 2. No abstract available.

PMID:
28583885
16.

Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.

Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB.

Sci Transl Med. 2017 May 31;9(392). pii: eaal5148. doi: 10.1126/scitranslmed.aal5148.

17.

IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.

Stabile LP, Egloff AM, Gibson MK, Gooding WE, Ohr J, Zhou P, Rothenberger NJ, Wang L, Geiger JL, Flaherty JT, Grandis JR, Bauman JE.

Oral Oncol. 2017 Jun;69:38-45. doi: 10.1016/j.oraloncology.2017.03.011. Epub 2017 Apr 9.

18.

Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.

Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, Kim S, Hirsch FR, Ellison K, Flaherty JT, Mills GB, Grandis JR.

JCI Insight. 2017 Mar 23;2(6):e90449. doi: 10.1172/jci.insight.90449.

19.

TMEM16A/ANO1 suppression improves response to antibody-mediated targeted therapy of EGFR and HER2/ERBB2.

Kulkarni S, Bill A, Godse NR, Khan NI, Kass JI, Steehler K, Kemp C, Davis K, Bertrand CA, Vyas AR, Holt DE, Grandis JR, Gaither LA, Duvvuri U.

Genes Chromosomes Cancer. 2017 Jun;56(6):460-471. doi: 10.1002/gcc.22450. Epub 2017 Apr 3.

20.

Nonpromoter methylation of the CDKN2A gene with active transcription is associated with improved locoregional control in laryngeal squamous cell carcinoma.

Ben-Dayan MM, Ow TJ, Belbin TJ, Wetzler J, Smith RV, Childs G, Diergaarde B, Hayes DN, Grandis JR, Prystowsky MB, Schlecht NF.

Cancer Med. 2017 Feb;6(2):397-407. doi: 10.1002/cam4.961. Epub 2017 Jan 19.

21.

Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations.

Li YY, Chung GT, Lui VW, To KF, Ma BB, Chow C, Woo JK, Yip KY, Seo J, Hui EP, Mak MK, Rusan M, Chau NG, Or YY, Law MH, Law PP, Liu ZW, Ngan HL, Hau PM, Verhoeft KR, Poon PH, Yoo SK, Shin JY, Lee SD, Lun SW, Jia L, Chan AW, Chan JY, Lai PB, Fung CY, Hung ST, Wang L, Chang AM, Chiosea SI, Hedberg ML, Tsao SW, van Hasselt AC, Chan AT, Grandis JR, Hammerman PS, Lo KW.

Nat Commun. 2017 Jan 18;8:14121. doi: 10.1038/ncomms14121.

22.

Cancer genomics: Spot the difference.

Peyser ND, Grandis JR.

Nature. 2017 Jan 12;541(7636):162-163. doi: 10.1038/nature21112. Epub 2017 Jan 4. No abstract available. Erratum in: Nature. 2017 Feb 1;542(7639):42.

PMID:
28052059
23.

Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients.

Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR.

Clin Cancer Res. 2017 Jun 15;23(12):3072-3083. doi: 10.1158/1078-0432.CCR-16-2203. Epub 2016 Dec 16.

24.

Head and neck cancer in 2016: A watershed year for improvements in treatment?

Algazi AP, Grandis JR.

Nat Rev Clin Oncol. 2017 Feb;14(2):76-78. doi: 10.1038/nrclinonc.2016.196. Epub 2016 Dec 6. No abstract available.

PMID:
27922045
25.

A sensible approach to targeting STAT3-mediated transcription.

Bhola NE, Johnson DE, Grandis JR.

Ann Transl Med. 2016 Oct;4(Suppl 1):S57. No abstract available.

26.

Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer.

Peyser ND, Pendleton K, Gooding WE, Lui VW, Johnson DE, Grandis JR.

PLoS One. 2016 Nov 17;11(11):e0166185. doi: 10.1371/journal.pone.0166185. eCollection 2016.

27.

Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer.

Lesseur C, Diergaarde B, Olshan AF, Wünsch-Filho V, Ness AR, Liu G, Lacko M, Eluf-Neto J, Franceschi S, Lagiou P, Macfarlane GJ, Richiardi L, Boccia S, Polesel J, Kjaerheim K, Zaridze D, Johansson M, Menezes AM, Curado MP, Robinson M, Ahrens W, Canova C, Znaor A, Castellsagué X, Conway DI, Holcátová I, Mates D, Vilensky M, Healy CM, Szeszenia-Dąbrowska N, Fabiánová E, Lissowska J, Grandis JR, Weissler MC, Tajara EH, Nunes FD, de Carvalho MB, Thomas S, Hung RJ, Peters WH, Herrero R, Cadoni G, Bueno-de-Mesquita HB, Steffen A, Agudo A, Shangina O, Xiao X, Gaborieau V, Chabrier A, Anantharaman D, Boffetta P, Amos CI, McKay JD, Brennan P.

Nat Genet. 2016 Dec;48(12):1544-1550. doi: 10.1038/ng.3685. Epub 2016 Oct 17.

28.

Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation.

Kiesel BF, Parise RA, Guo J, Huryn DM, Johnston PA, Colombo R, Sen M, Grandis JR, Beumer JH, Eiseman JL.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1225-1235. Epub 2016 Oct 24.

29.

Treatment of head and neck cancer in the elderly.

Hartmann S, Grandis JR.

Expert Opin Pharmacother. 2016 Oct;17(14):1903-21. doi: 10.1080/14656566.2016.1220540. Epub 2016 Aug 16. Review.

PMID:
27643444
30.

Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors.

LaPorte MG, Wang Z, Colombo R, Garzan A, Peshkov VA, Liang M, Johnston PA, Schurdak ME, Sen M, Camarco DP, Hua Y, Pollock NI, Lazo JS, Grandis JR, Wipf P, Huryn DM.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3581-5. doi: 10.1016/j.bmcl.2016.06.017. Epub 2016 Jun 9.

31.

HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.

Hartmann S, Bhola NE, Grandis JR.

Clin Cancer Res. 2016 Aug 15;22(16):4005-13. doi: 10.1158/1078-0432.CCR-16-0951. Epub 2016 Jul 1. Review.

32.

New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints.

Wang VE, Grandis JR, Ko AH.

Clin Cancer Res. 2016 Sep 1;22(17):4283-90. doi: 10.1158/1078-0432.CCR-16-0292. Epub 2016 Jul 1. Review.

33.

Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane.

Bauman JE, Zang Y, Sen M, Li C, Wang L, Egner PA, Fahey JW, Normolle DP, Grandis JR, Kensler TW, Johnson DE.

Cancer Prev Res (Phila). 2016 Jul;9(7):547-57. doi: 10.1158/1940-6207.CAPR-15-0290. Epub 2016 Jun 23.

34.

The non-coding landscape of head and neck squamous cell carcinoma.

Zou AE, Zheng H, Saad MA, Rahimy M, Ku J, Kuo SZ, Honda TK, Wang-Rodriguez J, Xuan Y, Korrapati A, Yu V, Singh P, Grandis JR, King CC, Lippman SM, Wang XQ, Hinton A, Ongkeko WM.

Oncotarget. 2016 Aug 9;7(32):51211-51222. doi: 10.18632/oncotarget.9979.

35.

STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.

Peyser ND, Wang L, Zeng Y, Acquafondata M, Freilino M, Li H, Sen M, Gooding WE, Satake M, Wang Z, Johnson DE, Grandis JR.

Cancer Prev Res (Phila). 2016 Aug;9(8):657-63. doi: 10.1158/1940-6207.CAPR-16-0089. Epub 2016 Jun 7.

36.

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.

Geiger JL, Bauman JE, Gibson MK, Gooding WE, Varadarajan P, Kotsakis A, Martin D, Gutkind JS, Hedberg ML, Grandis JR, Argiris A.

Head Neck. 2016 Dec;38(12):1759-1764. doi: 10.1002/hed.24501. Epub 2016 May 27.

PMID:
27232378
37.

Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.

Argiris A, Bauman JE, Ohr J, Gooding WE, Heron DE, Duvvuri U, Kubicek GJ, Posluszny DM, Vassilakopoulou M, Kim S, Grandis JR, Johnson JT, Gibson MK, Clump DA, Flaherty JT, Chiosea SI, Branstetter B, Ferris RL.

Ann Oncol. 2016 Aug;27(8):1594-600. doi: 10.1093/annonc/mdw204. Epub 2016 May 13.

PMID:
27177865
38.

Corrigendum to "Cetuximab activity in dysplastic lesions of the upper aerodigestive tract" [Oral Oncol. 53 (2016) 60-66].

Khan Z, Epstein JB, Marur S, Boyd Gillespie M, Feldman L, Tsai HL, Zhang Z, Wang H, Sciubba J, Ferris RL, Grandis JR, Gibson M, Koch W, Tufano R, Westra W, Tsottles N, Ozawa H, Chung CH, Califano JA.

Oral Oncol. 2016 Jun;57:e8. doi: 10.1016/j.oraloncology.2016.03.018. Epub 2016 Apr 13. No abstract available.

PMID:
27085635
39.

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR.

J Clin Invest. 2016 Apr 1;126(4):1606. doi: 10.1172/JCI86862. Epub 2016 Apr 1. No abstract available.

40.

The degree of intratumor mutational heterogeneity varies by primary tumor sub-site.

Ledgerwood LG, Kumar D, Eterovic AK, Wick J, Chen K, Zhao H, Tazi L, Manna P, Kerley S, Joshi R, Wang L, Chiosea SI, Garnett JD, Tsue TT, Chien J, Mills GB, Grandis JR, Thomas SM.

Oncotarget. 2016 May 10;7(19):27185-98. doi: 10.18632/oncotarget.8448.

41.

MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.

Wen Y, Li H, Zeng Y, Wen W, Pendleton KP, Lui VW, Egloff AM, Grandis JR.

Oncotarget. 2016 Apr 26;7(17):23300-11. doi: 10.18632/oncotarget.8188.

42.

The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.

Geiger JL, Grandis JR, Bauman JE.

Oral Oncol. 2016 May;56:84-92. doi: 10.1016/j.oraloncology.2015.11.022. Epub 2015 Dec 28. Review.

43.

Cetuximab activity in dysplastic lesions of the upper aerodigestive tract.

Khan Z, Epstein JB, Marur S, Gillespie MB, Feldman L, Tsai HL, Zhang Z, Wang H, Sciubba J, Ferris R, Grandis JR, Gibson M, Koch W, Tufano R, Westra W, Tsottles N, Ozawa H, Chung C, Califano JA.

Oral Oncol. 2016 Feb;53:60-6. doi: 10.1016/j.oraloncology.2015.11.016. Epub 2015 Dec 10.

PMID:
26686755
44.

Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts.

Li H, Wheeler S, Park Y, Ju Z, Thomas SM, Fichera M, Egloff AM, Lui VW, Duvvuri U, Bauman JE, Mills GB, Grandis JR.

Mol Cancer Res. 2016 Mar;14(3):278-86. doi: 10.1158/1541-7786.MCR-15-0354. Epub 2015 Dec 18.

45.

Ultrasound Targeted Microbubble Destruction-Mediated Delivery of a Transcription Factor Decoy Inhibits STAT3 Signaling and Tumor Growth.

Kopechek JA, Carson AR, McTiernan CF, Chen X, Hasjim B, Lavery L, Sen M, Grandis JR, Villanueva FS.

Theranostics. 2015 Oct 16;5(12):1378-87. doi: 10.7150/thno.12822. eCollection 2015.

46.

Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.

Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL.

Cancer Res. 2016 Jan 15;76(2):440-52. doi: 10.1158/0008-5472.CAN-15-1640-T. Epub 2015 Dec 16.

47.

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR.

J Clin Invest. 2016 Jan;126(1):169-80. doi: 10.1172/JCI82066. Epub 2015 Nov 30. Erratum in: J Clin Invest. 2016 Apr 1;126(4):1606.

48.

Nucleic acid targeting: towards personalized therapy for head and neck cancer.

Parsel SM, Grandis JR, Thomas SM.

Oncogene. 2016 Jun 23;35(25):3217-26. doi: 10.1038/onc.2015.424. Epub 2015 Nov 23. Review.

49.

PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.

Liao HW, Hsu JM, Xia W, Wang HL, Wang YN, Chang WC, Arold ST, Chou CK, Tsou PH, Yamaguchi H, Fang YF, Lee HJ, Lee HH, Tai SK, Yang MH, Morelli MP, Sen M, Ladbury JE, Chen CH, Grandis JR, Kopetz S, Hung MC.

J Clin Invest. 2015 Dec;125(12):4529-43. doi: 10.1172/JCI82826. Epub 2015 Nov 16.

50.

MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer.

Chapman BV, Wald AI, Akhtar P, Munko AC, Xu J, Gibson SP, Grandis JR, Ferris RL, Khan SA.

BMC Cancer. 2015 Nov 6;15:861. doi: 10.1186/s12885-015-1888-3.

Supplemental Content

Loading ...
Support Center